Related Experiment Video
Updated: Jul 4, 2026
06:51
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
EndD mediates butyrate-dependent toxin release in Clostridioides difficile
Horia A Dobrila1,2,3, Henrieta Licha1, Andrew J Hryckowian1,2
1Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Biorxiv : the Preprint Server for Biology
|July 3, 2026
Summary
Butyrate, a gut microbe byproduct, increases Clostridioides difficile toxin release. This study identifies a novel endolysin, EndD, and its regulator SigK, crucial for this process, offering new therapeutic targets for C. difficile infections.
Area of Science:
- Microbiology
- Molecular Biology
- Gut Microbiome Research
Background:
- Clostridioides difficile infections (CDIs) pose a significant health threat, with current treatments facing limitations like antibiotic resistance and questions about microbiome restoration therapy (MRT) sustainability.
- A dysbiotic gut microbiome is a primary risk factor for CDI, highlighting the need to understand host-microbe interactions for precise therapeutic development.
- Emerging evidence implicates butyrate, a gut microbiome metabolite, in C. difficile pathogenesis, particularly its role in toxin release.
Purpose of the Study:
- To elucidate the mechanism behind butyrate-dependent toxin release in C. difficile.
- To identify the specific molecules and genetic factors involved in this process.
- To provide a deeper understanding of C. difficile pathogenesis for future therapeutic strategies.
Main Methods:
- Investigated butyrate's effect on toxin release pathways beyond known secretion and autolysis mechanisms.
- Utilized genetic and molecular biology techniques to identify and characterize the role of endolysin EndD in toxin release.
- Analyzed the regulation of endD expression, focusing on the sigma factor SigK and sporulation stages.
Main Results:
- Butyrate-enhanced toxin release is mediated by the endolysin EndD, not previously characterized pathways.
- EndD-dependent toxin release is condition-specific and regulated by the late-stage sporulation sigma factor SigK.
- This study uncovers a novel mechanism of toxin regulation in C. difficile.
Conclusions:
- Butyrate significantly influences C. difficile pathogenesis through EndD-mediated toxin release.
- The regulation of endD by SigK provides critical insights into the molecular underpinnings of CDI.
- Findings pave the way for developing targeted therapies against C. difficile by interfering with this newly identified pathway.
Related Concept Videos
01:12Bacterial Toxins
Bacterial toxins are sophisticated virulence factors that enable pathogenic bacteria to interact with, invade, and damage host tissues. These toxins fall broadly into two types: protein exotoxins, which are secreted into the environment and target specific host receptors, and lipopolysaccharide endotoxins, which are structural components of the bacterial outer membrane released primarily during bacterial lysis or membrane shedding. Exotoxins generally act more selectively, binding to cell...
01:18Dysbiosis of the Gut Microbiota
The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.Dysbiosis is often characterized by reduced microbial...
01:18Functions of the Gut Microbiota
The gut microbiota includes trillions of microorganisms that colonize the human gastrointestinal tract, including bacteria, archaea, viruses, and fungi. This complex ecosystem plays a critical role in maintaining intestinal and systemic health. Most of these microbes inhabit the large intestine, establishing a relatively stable and diverse community that contributes to gut homeostasis through various metabolic, immunological, and protective mechanisms.Dominant bacterial phyla, such as...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:27Microbiota of the Large Intestine
The large intestine hosts the most densely populated microbial ecosystem in the human body. This complex community primarily consists of anaerobic bacteria, with Bacillota (formerly Firmicutes) and Bacteroidota (formerly Bacteroidetes) as the predominant groups. The distribution of these microbes varies along different sections of the large intestine, influenced by local environmental factors such as oxygen availability and nutrient composition.The cecum, located at the beginning of the large...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...